Exhibit 99.1
Quanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2018
65% Q4 revenue growth; 65% full year growth
Lexington, Mass. — March 7, 2019 —Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the three months and twelve months ended Dec. 31, 2018.
“This past quarter has been highly productive, capping off a strong year of accelerating growth, achieving all our key milestones, and positioning us very well for 2019,” said Kevin Hrusovsky, Chief Executive Officer, President and Chairman, Quanterix. “Our Simoa technology is at the forefront of the biomarker revolution, which has gained considerable traction as biomarkers are increasingly being recognized for their promise to transform treatment options by accelerating the development of more effective and safer drugs for all disease categories, and monitoring patient response to treatment therapies to ensure their efficacy and safety. Longer term, we see the promise of Simoa biomarker assays being deployed as health screens to see disease very early in the disease cascade when treatments are most effective. We have been impressed with the acceleration of third-party, peer-reviewed publications and the resulting body of evidence showing the promise for Simoa blood based biomarker assays enabling early ‘pre-symptomatic’ detection of neurological diseases and cancers.”
Fourth Quarter 2018 Financial Highlights
Key financial results for the fourth quarter are shown below:
· Q4 revenue of $10.9M versus prior year Q4 of $6.6M, an increase of 65%.
· Q4 product revenue was $7.5M versus prior year Q4 of $4.1M, an increase of 83%.
· Q4 Service and Other revenue totaled $3.4M versus prior year Q4 of $2.2M, an increase of 52%.
· Q4 gross margin percent totaled 48.2%, a 450 basis point improvement over the 43.7% in Q4 2017.
YTD 2018 Financial Highlights
Key financial results for 2018 YTD are shown below:
· YTD revenue of $37.6M versus prior year $22.9M, an increase of 65%.
· YTD product revenue of $23.4M versus prior year $14.1M, an increase of 65%.
· YTD Service and Other revenue of $12.1M versus prior year $7.7M, an increase of 58%.
· YTD Collaboration revenue of $2.15M versus prior year $1.07M, an increase of 100%.
· YTD gross margin percent totaled 47.8%, a 410 basis point improvement over the 43.7% for full year 2017.
Excluding a one-time collaboration revenue item of $1.1M, total YTD revenue growth would have been 60%. See “Non-GAAP Financial Measures” below.
Fourth Quarter and Full Year 2018 Business Highlights
· Gained unrestricted rights back for its Simoa technology in IVD markets with the termination of a license agreement with bioMérieux.
· Third-party, peer-reviewed publications continued to increase with more than 40 new publications featuring Simoa technology in Q4 alone, and >200 during the full year, bringing the total to over 400.
· Acquired Aushon BioSystems and successfully integrated the two companies. The acquisition included a CLIA certified laboratory, expanding services and accelerating entry into pharmaceutical drug trial services, as well as access to novel immunoassay technology to which Simoa sensitivity algorithms are being applied to deliver next generation Simoa capabilities.
· Adoption of proprietary Neurofilament light chain (NfL) assay, a biomarker previously measured only in cerebral spinal fluid (CSF), but by using Simoa, researchers have shown it can be measured in blood and correlated to CSF results. This advance is enabling novel applications critical for advancing early detection, treatment and prevention of neurological diseases, including multiple sclerosis (MS); Parkinson’s disease; Alzheimer’s disease; brain cancer; and traumatic brain injuries (TBIs).
· Invited by the FDA and presented on progress and the potential future for the NfL biomarker to agency officials.
· Launched a test bed, early access program for the SP-X™ Imaging and Analysis System with a 10-plex Simoa cytokine panel for oncology research and drug development.
· Increased employee headcount from 126 at Dec. 31, 2017 to 177 at Dec. 31, 2018 (>40%) and expanded the leadership team with the recent hiring of Jackson Streeter, M.D. to lead corporate development and strategy, formerly chief medical officer and chief executive officer of Banyan Biomarkers; and Mary-Ellen Cortizas to lead the Accelerator Lab, formely founder and chief operating officer of Claritas Genomics.
· Added to the Nasdaq Biotechnology Index (NBI) as part of the annual re-ranking, and attracted additional analyst coverage.
· Participated in first EU Powering Precision Health Summit, which was a highly productive meeting of leading researchers, key opinion leaders, and other stakeholders in precision health.
· Reinforced the Company’s digital biomarker position through presentations at PULSE The Atlantic Summit on Health Care, The Lake Nona Impact Forum, and MedCity Converge, as well as the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, where the Company had a record number of posters/presentations mentioning the use of Quanterix’ serum NfL assay for a wide range of clinical studies in MS disease progression and monitoring.
Conference Call
In conjunction with this announcement, Quanterix Corporation will host a conference call on March 7, 2019, at 4:30 p.m., EST to discuss the Company’s financial results and business outlook. To access this call, dial (833) 686-9351 for domestic callers, or (612) 979-9890 for international callers. Please reference the following conference ID: 3288482.
A live webcast will be accessible on the Investors section of Quanterix’ website: http://www.quanterix.com. The webcast will be available on the Company’s website for one year following completion of the call.
Financial Highlights (in thousands)
Quanterix Statement of Operations
| | Q4 2018 | | Q4 2017 | | FY 2018 | | FY 2017 | |
Product revenue | | $ | 7,458 | | $ | 4,068 | | $ | 23,365 | | $ | 14,124 | |
Service and other revenue | | 3,419 | | 2,251 | | 12,118 | | 7,675 | |
Collaboration revenue | | — | | 269 | | 2,149 | | 1,074 | |
Total revenue | | $ | 10,877 | | $ | 6,588 | | $ | 37,632 | | $ | 22,873 | |
| | | | | | | | | |
Cost of product revenue | | $ | 3,717 | | $ | 2,169 | | $ | 12,712 | | $ | 7,741 | |
Cost of service revenue | | 1,916 | | 1,539 | | 6,936 | | 5,145 | |
Gross profit | | $ | 5,244 | | $ | 2,880 | | $ | 17,984 | | $ | 9,987 | |
| | | | | | | | | |
Research and development | | $ | 3,893 | | $ | 3,873 | | $ | 15,292 | | $ | 16,124 | |
Selling, general and administrative | | 8,865 | | 5,391 | | 29,120 | | 17,776 | |
Stock comp expense included in operating expenses | | 1,433 | | 710 | | 4,656 | | 2,092 | |
Total operating expenses | | $ | 14,191 | | $ | 9,974 | | $ | 49,068 | | $ | 35,992 | |
| | | | | | | | | |
Interest income (expense), net | | 25 | | (217 | ) | 46 | | (952 | ) |
Other income (expense), net | | 79 | | (73 | ) | (7 | ) | (62 | ) |
Net loss | | $ | (8,843 | ) | $ | (7,384 | ) | $ | (31,045 | ) | $ | (27,019 | ) |
Quanterix Balance Sheet
| | 12/31/18 | | 12/31/17 | |
Cash (including restricted cash) | | $ | 45,429 | | $ | 79,682 | |
AR | | 6,792 | | 5,599 | |
Inventory | | 5,962 | | 3,571 | |
Prepaid and other | | 2,330 | | 400 | |
Total current assets | | 60,513 | | 89,252 | |
| | | | | |
Property and equipment, net | | 2,923 | | 1,874 | |
Intangible assets and goodwill | | 3,656 | | 0 | |
Other non-current assets | | 536 | | 653 | |
Total assets | | $ | 67,628 | | $ | 91,779 | |
| | | | | |
Accounts payable/accrued expenses | | $ | 12,220 | | $ | 9,736 | |
Deferred revenue | | 5,437 | | 4,942 | |
Current portion of long term debt | | 0 | | 5,036 | |
Total current liabilities | | 17,657 | | 19,714 | |
| | | | | |
Deferred revenue, net of current portion | | 520 | | 1,709 | |
Long term debt | | 7,623 | | 4,346 | |
Other non-current liabilities | | 272 | | 144 | |
Total liabilities | | $ | 26,072 | | $ | 25,913 | |
| | | | | |
Total stockholders equity | | 41,556 | | 65,866 | |
| | | | | |
Total liabilities and stockholders equity | | $ | 67,628 | | $ | 91,779 | |
About Quanterix
Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts. For additional Information, please visit https://www.quanterix.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,”
“intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Non-GAAP Financial Measures
To supplement the Company’s financial statements presented on a GAAP basis, the Company discloses below non-GAAP revenue, revenue growth, gross profit and gross margin that excludes $1.1M in non-recurring revenue recognized in 2018 in connection with the termination of a license agreement. Management uses these non-GAAP measures to evaluate the Company’s operating performance. Management believes that such measures are important in comparing current results with prior period results, and is useful to investors and financial analysts in assessing the Company’s operating performance. The non-GAAP financial information presented here should be considered in conjunction with, and not as a substitute for the financial information presented in accordance with GAAP.
Reconciliation of non-GAAP Financials
(in thousands)
(unaudited)
| | 2018 | | 2017 | | | |
| | Twelve months ended
December 31, | | % Change | |
| | | | | | | |
Total revenue | | $ | 37,632 | | $ | 22,874 | | 65 | % |
Subtract | | | | | | | |
Non-recurring license revenue | | (1,073 | ) | — | | | |
Non-GAAP total revenue | | $ | 36,559 | | $ | 22,874 | | 60 | % |
| | | | | | | |
Gross profit | | $ | 17,984 | | $ | 9,987 | | | |
Subtract | | | | | | | |
Non-recurring license revenue | | (1,073 | ) | — | | | |
Non-GAAP gross profit | | $ | 16,911 | | $ | 9,987 | | | |
Gross margin | | 47.8 | % | 43.7 | % | | |
Non-GAAP gross margin | | 46.3 | % | 43.7 | % | | |
Contacts:
Quanterix, Inc.
Joseph Driscoll, CFO 617-301-9495
jdriscoll@quanterix.com
PAN Communications
Lindsay Poole, 617-502-4300
quanterix@pancomm.com
